A Phase 3 interventional study of Pitavastatin and Atorvastatin in Primary Hypercholesterolemia and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 192 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-01-12.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 4th largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 2nd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2005.
This study's enrollment of 830 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 200 across the 19 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
11 studies in Hypercholesterolemia by Kowa Company, Ltd.: 1 open now, 1 under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Hypercholesterolemia by Kowa Company, Ltd., this one is the 4th largest by enrollment, is one of 4 that started in 2005, is one of 10 in phase 3, and was the 1st registered.
Kowa Company, Ltd.’s Hypercholesterolemia studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing pitavastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kowa Company, Ltd.’s 11 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.
Following a wash-out dietary lead-in period, patients will receive either Atorvastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 830 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12
Time frame: Baseline to 12 weeks
Percent Change From Baseline in Total Cholesterol (TC)
Percent change in total cholesterol from baseline to Week 12
Time frame: Baseline to 12 Weeks
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
percent change from baseline in high density lipoprotein-cholesterol (HDL-C)
Time frame: Baseline to 12 weeks
TC:HDL-C Ratio
Ratio of mean total cholesterol to mean HDL-C at 12 weeks
Time frame: 12 weeks
Triglycerides (TG)
mean triglycerides at 12 weeks
Time frame: 12 weeks
Non-HDL:HDL Ratio
Ratio of non-HDL to HDL at 12 weeks
Time frame: 12 weeks
Apolipoprotein B (Apo B)
Apolipoprotein B at 12 weeks
Time frame: 12 weeks
Apolipoprotein-A1 (Apo-A1)
Apolipoprotein-A1 at 12 weeks
Time frame: 12 weeks
Apo-B:Apo-A1 Ratio
Ratio of Apo-B to Apo-A1 at 12 weeks
Time frame: 12 weeks
High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks
high sensitivity C-reactive protein (hs-CRP) at 12 weeks
Time frame: 12 weeks
Oxidized LDL at 12 Weeks
oxidized low density lipoprotein at 12 weeks
Time frame: 12 weeks
National Cholesterol Education Program [NCEP]LDL-C Target Attainment
Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)
Time frame: up to 12 weeks
First Patient In: 4 October 2005 Last Patient Out: 8 November 2006 A total of 39 investigators at 39 sites in India, Russia, Spain and Denmark received IRB approval to participate in this study and screened and randomized patients.
| Milestone | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Started | 321 | 103 | 303 | 103 |
| Safety population | 316 | 102 | 300 | 103 |
| Completed | 301 | 98 | 288 | 100 |
| Not completed | 20 | 5 | 15 | 3 |
| percent change | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12 | -37.89 ± 13.841 | -38.76 ± 14.582 | -45.5 ± 14.005 | -43.9 ± 15.853 |
Percent change in total cholesterol from baseline to Week 12
| percent change | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) | -27.57 ± 10.359 | -28.92 ± 11.441 | -33.09 ± 10.732 | -32.99 ± 12.073 |
percent change from baseline in high density lipoprotein-cholesterol (HDL-C)
| percent change | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) | 4.28 ± 16.501 | 3.42 ± 16.820 | 4.93 ± 16.629 | 2.63 ± 13.803 |
Ratio of mean total cholesterol to mean HDL-C at 12 weeks
| ratio | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| TC:HDL-C Ratio | 4.018 ± 1.1294 | 3.763 ± 0.8667 | 3.583 ± 1.0961 | 3.79 ± 1.2052 |
mean triglycerides at 12 weeks
| mg/dL | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Triglycerides (TG) | 132.4 ± 59.82 | 122.2 ± 57.09 | 124.4 ± 64.91 | 122.6 ± 59.01 |
Ratio of non-HDL to HDL at 12 weeks
| Measure | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Non-HDL:HDL Ratio | 2.993 ± 1.0935 | 2.770 ± 0.8846 | 2.601 ± 1.0961 | 2.710 ± 1.1771 |
Apolipoprotein B at 12 weeks
| mg/dL | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Apolipoprotein B (Apo B) | 114.5 ± 23.36 | 111.1 ± 25.12 | 102.3 ± 22.04 | 102.4 ± 22.13 |
Apolipoprotein-A1 at 12 weeks
| mg/dL | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Apolipoprotein-A1 (Apo-A1) | 164.6 ± 29.10 | 166 ± 26.8 | 166.9 ± 28.01 | 160.9 ± 26.58 |
Ratio of Apo-B to Apo-A1 at 12 weeks
| ratio | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Apo-B:Apo-A1 Ratio | 0.72 ± 0.228 | 0.68 ± 0.181 | 0.64 ± 0.198 | 0.66 ± 0.205 |
high sensitivity C-reactive protein (hs-CRP) at 12 weeks
| mg/L | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| High Sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks | 2.87 ± 5.101 | 2.39 ± 3.053 | 3.12 ± 5.186 | 2.56 ± 2.958 |
oxidized low density lipoprotein at 12 weeks
| U/L | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| Oxidized LDL at 12 Weeks | 59.93 ± 14.96 | 58.59 ± 14.679 | 54.32 ± 13.496 | 54.70 ± 17.865 |
Number of patients achieving NCEP LDL-C target (LDL-C less than or equal to 130 mg/dL)
| Patients | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| National Cholesterol Education Program [NCEP]LDL-C Target Attainment | 179 | 67 | 232 | 72 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 2 mg QD | — | 3/316 (0.9%) | 22/316 (7%) |
| Atorvastatin 10 mg QD | — | 1/102 (1%) | 6/102 (5.9%) |
| Pitavastatin 4 mg QD | — | 1/300 (0.3%) | 17/300 (5.7%) |
| Atorvastatin 20 mg QD | — | 2/103 (1.9%) | 4/103 (3.9%) |
| Event | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| angina unstableCardiac disorders | 0/316 | 1/102 | 0/300 | 0/103 |
| angina pectorisCardiac disorders | 0/316 | 0/102 | 0/300 | 1/103 |
| deafness neurosensoryEar and labyrinth disorders | 0/316 | 0/102 | 0/300 | 1/103 |
| encephalopathyNervous system disorders | 0/316 | 0/102 | 0/300 | 1/103 |
| myocardial infarctionCardiac disorders | 0/316 | 0/102 | 1/300 | 0/103 |
| pruritus generalizedSkin and subcutaneous tissue disorders | 1/316 | 0/102 | 0/300 | 0/103 |
| acute myocardial infarctionCardiac disorders | 1/316 | 0/102 | 0/300 | 0/103 |
| burning sensationNervous system disorders | 1/316 | 0/102 | 0/300 | 0/103 |
| abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/316 | 0/102 | 0/300 | 0/103 |
| Event | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|---|---|
| nasopharyngitisInfections and infestations | 10/316 | 4/102 | 8/300 | 3/103 |
| constipationGastrointestinal disorders | 7/316 | 1/102 | 3/300 | 0/103 |
| myalgiaMusculoskeletal and connective tissue disorders | 5/316 | 1/102 | 6/300 | 1/103 |
| Age, Categorical(Participants) | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 219 | 75 | 207 | 73 | 574 |
| >=65 years | 97 | 27 | 93 | 30 | 247 |
| Age Continuous(years) | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|---|---|
| Mean | 58.4 ± 9.51 | 59.2 ± 8.63 | 57.9 ± 10.1 | 58.0 ± 9.14 | 58.3 ± 9.58 |
| Sex: Female, Male(Participants) | Pitavastatin 2 mg QD | Atorvastatin 10 mg QD | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|---|---|
| Female | 174 | 50 | 164 | 55 | 443 |
| Male | 142 | 52 | 136 | 48 | 378 |
Showing the first 100 of 192 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2005 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pitavastatin · Atorvastatin